Daptomycin Resistance in Clinical MRSA Strains Is Associated with a High Biological Fitness Cost.

ABSTRACT: Daptomycin remains as one of the main treatment options for Methicillin-Resistant Staphylococcus aureus (MRSA). Sporadic resistance cases reported in patients treated with either daptomycin or glycopeptides are a growing concern. In a previous study, we described a clinical case of a patient with a community-acquired MRSA infection resistant to daptomycin and with intermediate resistance to vancomycin who developed a recurrent infection with a susceptible isogenic strain. In the present work, we further investigated the sequential events to determine whether the switch from a daptomycin resistance to a susceptible phenotype was due to a phenomenon of resistance reversion or recurrent infection with a susceptible strain. Pairwise competition experiments showed that the susceptible clinical

SUBMITTER: Roch M 

PROVIDER: S-EPMC5723333 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature